{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:34:57Z","timestamp":1778672097468,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T00:00:00Z","timestamp":1494547200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s11883-017-0666-x","type":"journal-article","created":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T02:39:13Z","timestamp":1494556753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations"],"prefix":"10.1007","volume":"19","author":[{"given":"Bhavin B.","family":"Adhyaru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,12]]},"reference":[{"issue":"31","key":"666_CR1","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1093\/eurheartj\/ehv182","volume":"36","author":"JG Robinson","year":"2015","unstructured":"\u2022 Robinson JG, Stone NJ. The 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. Eur Heart J. 2015;36(31):2110\u20138. This article summarizes the 2013 ACC\/AHA guidelines on lipid management and how it represents a paradigm shift from prior guidelines. It also introduces new evidence and the rationale for some of the controversies of the 2013 ACC\/AHA guideline","journal-title":"Eur Heart J"},{"issue":"2","key":"666_CR2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccl.2015.02.001","volume":"33","author":"BB Adhyaru","year":"2015","unstructured":"\u2022 Adhyaru BB, Jacobson TA. New cholesterol guidelines for the management of atherosclerotic cardiovascular disease risk: a comparison of the 2013 American College of Cardiology\/American Heart Association cholesterol guidelines with the 2014 National Lipid Association recommendations for patient-centered management of dyslipidemia. Cardiol Clin. 2015;33(2):181\u201396. This article highlights some of the important differences in the NLA and ACC\/AHA guidelines","journal-title":"Cardiol Clin"},{"issue":"1","key":"666_CR3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"DM Lloyd-Jones","year":"2016","unstructured":"\u2022\u2022 Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68(1):92\u2013125. This ACC consensus document summarizes in detail the recommendations of the ACC based on new clinical trial evidence and highlights the role of LDL-C thresholds as well as special populations. Also, it gives advice on the use of the nonstatins, including ezetimibe, bile acid sequestrants, PCSK9 inhibitors, and niacin. In addition, it offers a pragmatic approach to lipid management, and gives guidance to clinicians when the evidence base is incomplete","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"666_CR4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jacl.2016.04.004","volume":"10","author":"CE Orringer","year":"2016","unstructured":"Orringer CE, Morris PB. Consensus between the American College of Cardiology and the National Lipid Association on the use of non-statin therapy for atherosclerotic cardiovascular disease prevention. J Clin Lipidol. 2016;10(3):458\u201361.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"666_CR5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","volume":"9","author":"TA Jacobson","year":"2015","unstructured":"\u2022 Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1\u2014full report. J Clin Lipidol. 2015;9(2):129\u201369. 2015 Part 1 Recommendations of the National Lipid Association after publication of the 2013 ACC\/AHA Cholesterol Guidelines. Emphasizes the importantce of patient centered care, the use of LDL and Non-HDL-C goals and targets, the use of nonstatins in further reducing LDL-C and ASCVD risk, the importance of LDL-C monitoring to assess the adequacy of the response to therapy, adherence to therapy, and to provide a monitoring metric that both patients and providers understand","journal-title":"J Clin Lipidol"},{"issue":"6 Suppl","key":"666_CR6","first-page":"S1-122","volume":"9","author":"TA Jacobson","year":"2015","unstructured":"\u2022\u2022 Jacobson TA, Maki KC, Orringer CE, et al. National Lipid Association Recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol. 2015;9(6 Suppl):S1-122\u2013e121. The Part 2 Recommendations of the NLA includes in depth recommendations about nutrition and lifestyle; management of cholesterol and ASCVD risk throughout the lifespan (pediatrics, adolescents, pregnancy, women, and elderly); special populations including those of different ethnicities (Hispanic, African American, South Asian, and Native Indian); populations at high ASCVD risk including HIV, RA, and CKD; team based collaborative care; and methods to improve adherence to therapies","journal-title":"J Clin Lipidol"},{"issue":"3","key":"666_CR7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","volume":"371","author":"MJ Landray","year":"2014","unstructured":"HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203\u201312.","journal-title":"N Engl J Med"},{"issue":"24","key":"666_CR8","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"WE Boden","year":"2011","unstructured":"AIM HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255\u201367.","journal-title":"N Engl J Med"},{"issue":"17","key":"666_CR9","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563\u201374.","journal-title":"N Engl J Med"},{"issue":"25","key":"666_CR10","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"\u2022\u2022 Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397. This landmark study is the first study to show a positive effect of adding non-statin therapy (ezetimibe) to moderate to high intensity statin therapy on ASCVD risk reduction.","journal-title":"N Engl J Med"},{"key":"666_CR11","doi-asserted-by":"crossref","unstructured":"Blazing MA, Giugliano RP, de Lemos JA, et al. On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). Am Heart J. 2016;182(182):89\u201396","DOI":"10.1016\/j.ahj.2016.09.004"},{"key":"666_CR12","unstructured":"Jarcho JA, Keaney JF. Proof that lower is better\u2014LDL cholesterol and IMPROVE-IT. New Engl J Med. 2015;372(25):2448, 13\u201350."},{"issue":"16","key":"666_CR13","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"\u2022 Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500\u20139. This landmark short-term safety study shows that the PCSK-9 inhibitor evolocumab is safe and has a potential important role in ASCVD risk reduction.","journal-title":"N Engl J Med"},{"issue":"16","key":"666_CR14","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"\u2022 Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489\u201399. This landmark short-term study shows that the PCSK-9 inhibitor alirocumab is safe and has a potential important role in ASCVD risk reduction","journal-title":"N Engl J Med"},{"key":"666_CR15","doi-asserted-by":"crossref","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713\u20131722","DOI":"10.1056\/NEJMoa1615664"},{"issue":"2","key":"666_CR16","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/FJC.0b013e31823a109f","volume":"59","author":"S Aggarwal","year":"2012","unstructured":"Aggarwal S, Loomba RS, Arora RR. Efficacy of colesevelam on lowering glycemia and lipids. J Cardiovasc Pharmacol. 2012;59(2):198\u2013205.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"9","key":"666_CR17","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","volume":"129","author":"DJ Rader","year":"2014","unstructured":"Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014;129(9):1022\u201332.","journal-title":"Circulation"},{"issue":"7","key":"666_CR18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11883-015-0516-7","volume":"17","author":"VG Bhoj","year":"2015","unstructured":"Bhoj VG, Sachais BS. Lipoprotein apheresis. Current Atherosclerosis Reports. 2015;17(7):39.","journal-title":"Current Atherosclerosis Reports"},{"issue":"22","key":"666_CR19","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","volume":"132","author":"SS Gidding","year":"2015","unstructured":"Gidding SS, Champagne MA, de Ferranti SD, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. 2015;132(22):2167\u201392.","journal-title":"Circulation"},{"issue":"3","key":"666_CR20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacl.2011.03.001","volume":"5","author":"AC Goldberg","year":"2011","unstructured":"Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on familial hypercholesterolemia. J Clin Lipidol. 2011;5(3):133\u201340.","journal-title":"J Clin Lipidol"},{"issue":"21","key":"666_CR21","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195\u2013207.","journal-title":"N Engl J Med"},{"issue":"17","key":"666_CR22","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/eurheartj\/ehw046","volume":"37","author":"PM Ridker","year":"2016","unstructured":"Ridker PM, Mora S, Rose L, Group JTS. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J. 2016;37(17):1373\u20139.","journal-title":"Eur Heart J"},{"issue":"18","key":"666_CR23","first-page":"2545","volume":"252","author":"Lipid Research Clinics Program","year":"1984","unstructured":"Lipid Research Clinics Program. JAMA. 1984;252(18):2545\u20138.","journal-title":"JAMA"},{"issue":"6","key":"666_CR24","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","volume":"8","author":"PL Canner","year":"1986","unstructured":"Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245\u201355.","journal-title":"J Am Coll Cardiol"},{"key":"666_CR25","doi-asserted-by":"crossref","unstructured":"Expert Panel on Detection E. Treatment of high blood cholesterol in A. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001, 285;(19):2486\u201397.","DOI":"10.1001\/jama.285.19.2486"},{"issue":"4","key":"666_CR26","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1161\/ATVBAHA.116.306887","volume":"36","author":"JG Robinson","year":"2016","unstructured":"Robinson JG, Ray K. Counterpoint: low-density lipoprotein cholesterol targets are not needed in lipid treatment guidelines. Arterioscler Thromb Vasc Biol. 2016;36(4):586\u201390.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9645","key":"666_CR27","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","volume":"372","author":"L Tavazzi","year":"2008","unstructured":"Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1231\u20139.","journal-title":"Lancet"},{"issue":"22","key":"666_CR28","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","volume":"357","author":"J Kjekshus","year":"2007","unstructured":"Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248\u201361.","journal-title":"N Engl J Med"},{"issue":"6","key":"666_CR29","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ejheart.2005.09.005","volume":"7","author":"J Kjekshus","year":"2005","unstructured":"Kjekshus J, Dunselman P, Blideskog M, et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail. 2005;7(6):1059\u201369.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"666_CR30","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1253\/circj.CJ-12-1062","volume":"77","author":"H Takano","year":"2013","unstructured":"Takano H, Mizuma H, Kuwabara Y, et al. Effects of pitavastatin in Japanese patients with chronic heart failure: the pitavastatin heart failure study (PEARL study). Circulation Journal: Official Journal of the Japanese Circulation Society. 2013;77(4):917\u201325.","journal-title":"Circulation Journal: Official Journal of the Japanese Circulation Society"},{"issue":"4","key":"666_CR31","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ejhf.247","volume":"17","author":"MJ Feinstein","year":"2015","unstructured":"Feinstein MJ, Jhund P, Kang J, et al. Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. Eur J Heart Fail. 2015;17(4):434\u201341.","journal-title":"Eur J Heart Fail"},{"issue":"24","key":"666_CR32","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/eurheartj\/ehv072","volume":"36","author":"D Preiss","year":"2015","unstructured":"Preiss D, Campbell RT, Murray HM, et al. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur Heart J. 2015;36(24):1536\u201346.","journal-title":"Eur Heart J"},{"issue":"24","key":"666_CR33","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1093\/eurheartj\/ehv133","volume":"36","author":"J Kjekshus","year":"2015","unstructured":"Kjekshus J. Are statins failing in heart failure? Eur Heart J. 2015;36(24):1502\u20134.","journal-title":"Eur Heart J"},{"key":"666_CR34","doi-asserted-by":"crossref","unstructured":"Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223\u20131230.","DOI":"10.1016\/S0140-6736(08)61239-8"},{"issue":"9784","key":"666_CR35","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181\u201392.","journal-title":"Lancet"},{"issue":"14","key":"666_CR36","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"BC Fellstrom","year":"2009","unstructured":"Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395\u2013407.","journal-title":"N Engl J Med"},{"key":"666_CR37","doi-asserted-by":"crossref","unstructured":"Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238\u201348.","DOI":"10.1056\/NEJMoa043545"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-017-0666-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-017-0666-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-017-0666-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T14:14:24Z","timestamp":1569334464000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-017-0666-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,12]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["666"],"URL":"https:\/\/doi.org\/10.1007\/s11883-017-0666-x","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,12]]},"article-number":"29"}}